Biogen Idec reported 2014 results that were slightly ..... earnings per share growth this year. Overall, Biogen 's dominant position in the multiple sclerosis ..... neurology contribute to its stable wide moat. Biogen 's 2014 results were impressive, with
Jan 29 (Reuters) - Biogen Idec Inc on Thursday reported higher-than-expected fourth-quarter profit on strong demand for its oral multiple sclerosis drug Tecfidera and issued a forecast for 2015 earnings far higher than Wall Street forecasts.
accumulate a lot of biotech names and participate in their big runs the past couple years. Names like Amgen AMGN and Biogen Idec BIIB contributed alongside a variety of other stocks like Southwest Airlines LUV, Micron Technology MU, and Charles
Jan 11 (Reuters) - Biogen Idec Inc on Sunday said it would buy small, privately-held Convergence Pharmaceuticals to acquire the U.K.-based company's portfolio of experimental drugs for chronic nerve pain.
recognizes their worth, paid off in a big way in 2014. Notably, big biotech and pharmaceutical holdings--such as Biogen Idec BIIB , Amgen AMGN, Eli Lilly LLY, Roche, and Novartis NVS--in all six funds posted strong returns for the second-straight
Name Star Rating Moat Rating Current Price (USD) Price/ FVE Fair Value Uncertainty Market Cap (USD Mil) % Stock Holdings Biogen BIIB 3 Wide 344.49 1.01 Medium 81,866 7.7 Amgen AMGN 4 Wide 164.53 0.92 Low 123,985 5.2 Eli Lilly LLY 2 Wide 69
Dec 2 (Reuters) - Biogen Idec Inc 's research chief on Tuesday said the company is planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque...
Dec 2 (Reuters) - Biogen Idec Inc 's research chief on Tuesday said the company was planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque...
share prices and contributing to its low uncertainty rating. However, new competition for Advate from the likes of Biogen Idec BIIB and Novo Nordisk NVO over the next few years could begin to erode the firm's dominant position in the U.S. market
Oct 22 (Reuters) - Biogen Idec Inc said on Wednesday sales of its big-selling new multiple sclerosis drug Tecfidera fell short of Wall Street's lofty expectations, and the company confirmed a serious...